Skip to main content

Table 4 Number of Patients with Data Available and Number Excluded due to Missing Dataa After METTb

From: Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

Variable

LV Fractional Shortening Z-scores

LV End-Diastolic Dimension Z-scores

LV End-Diastolic Posterior Wall Thickness Z-scores

LV Thickness to Dimension Ratio Z-scores

End-Diastolic Septal Thickness Z-scores

LV Mass Z-scores

NT-proBNP

Overall

n = 229

n = 224

n = 221

n = 228

n = 212

n = 214

n = 156

(n = 148)

(n = 146)

(n = 143)

(n = 146)

(n = 142)

(n = 140)

(n = 97)

AOST0121

n = 90

n = 85

n = 83

n = 89

n = 83

n = 82

n = 42

(n = 82)

(n = 80)

(n = 78)

(n = 80)

(n = 78)

(n = 77)

(n = 27)

P9754

n = 139

n = 139

n = 138

n = 139

n = 129

n = 132

n = 114

(n = 66)

(n = 66)

(n = 65)

(n = 66)

(n = 64)

(n = 63)

(n = 70)

  1. aNumber of patients with missing data in parenthesis for each variable
  2. bMETT minimum expected treatment time